We offer 1800+ tests in clinical, molecular and anatomic pathology.
With over 18 subspecialties and 60+ experts, we can help with even the most difficult cases.
Visit one of our 21 specimen collection sites.
NEWS & EVENTS
February 28, 2023
Dr. Lakshmi (Priya) Kunju names Director of the Division of Anatomic Pathology
It is with great pleasure that we announce Dr. Lakshmi (Priya) Kunju as our new Director of the Division of Anatomic Pathology (AP) effective Wednesday, March 1, 2023.
February 7, 2023
Drs. Asma Nusrat and Charles Parkos Named 2022 AAAS Fellows
Congratulations are due to Dr. Asma Nusrat, F. Peyton Rous Professor of Experimental Pathology and Director of Experimental Pathology, and Dr. Charles Parkos, Carl V. Weller Professor and Chair of Pathology, on being named 2022 American Association for the Advancement of Science Fellows.
January 25, 2023
Kim lab identifies the niche and mobilization mechanism for bone marrow innate lymphoid cell progenitors
The laboratory of Dr. Chang Kim, recently published a high-impact study that elucidates the bone marrow niche and mechanisms by which innate lymphoid cells differentiate between those which remain in the bone marrow and those which emigrate to the rest of the body.
NGS Solid Tumor Panel
Molecular testing of solid tumor neoplasms - particularly advanced-stage cancer. This DNA and RNA based, NGS test targets 50 actionable genes (35 mutations, 19 amplifications, 21 - fusions). Requires <1mm2 of tissue (as little as 100 tumor cells) and a low 3% QNS rate.
NEW TREATMENT OPTION FOR METASTATIC BREAST CANCER
MLabs offers NGS Solid Tumor Panel and Single gene test to detect PIK3CA for FDA approved therapy alpelisib (Piqray®).
Myeloid NGS Panel
This test is intended for the molecular evaluation of myeloid neoplasms including myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), myelodysplastic/myeloproliferative neoplasms, acute myeloid leukemias (AML), mastocytosis and myeloid neoplasms with eosinophilia and gene rearrangement.
Erdafitinib (Balversa™) is an FGFR-inhibitor that is FDA-approved for the treatment of metastatic urothelial cancers harboring susceptible mutations or translocations involving FGFR2 or FGFR3.
NR4A3 (9q22-9q31) Rearrangement (FISH)
NR4A3 encodes an orphan nuclear receptor. Rearrangements of NR4A3 occur in more than 80% of extraskeletal myxoid chondrosarcoma (EMC) as well as in salivary acinic cell carcinoma (AciCC), driving tumorigenesis.
TFE3 Rearrangement (FISH)
Detecting rearrangements involving the TFE3 gene region (Xp11.2) via fluorescence in situ hybridization (FISH) to qualitatively assess for the presence of TFE3 translocations that are associated with certain subtypes of renal cell carcinoma. Testing for TFE3 gene rearrangement may aid in the diagnosis and classification of renal tumors.